Ascletis Plans China Submission After Positive Denifanstat Phase III Acne Results

Validation Of FASN Inhibition Approach

 
• By Sushmita Panda
  
Acne
Promising Phase III results in China trial for Ascletis/Sagimet's novel acne contender. (Shutterstock)
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Dermatological

More from Therapy Areas